Kaempferol regulates MAPKs and NF-κB signaling pathways to attenuate LPS-induced acute lung injury in mice

Int Immunopharmacol. 2012 Oct;14(2):209-16. doi: 10.1016/j.intimp.2012.07.007. Epub 2012 Jul 23.

Abstract

Recent studies show that mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-κB) signaling pathways are two pivotal roles contributing to the development of lipopolysaccharide (LPS)-induced acute lung injury (ALI). The present study aimed to investigate the protective effect of kaempferol (Kae), a naturally occurring flavonoid compound, on ALI and explore its possible mechanisms. Male BALB/c mice with ALI, induced by intranasal instillation of LPS, were treated or not with Kae (100 mg/kg, intragastrically) 1h prior to LPS exposure. Kae treatment attenuated pulmonary edema of mice with ALI after LPS challenge, as it markedly decreased the lung W/D ratio of lung samples, protein concentration and the amounts of inflammatory cells in BALF. Similarly, LPS mediated overproduction of proinflammatory cytokines in BALF, including TNF-α, IL-1β and IL-6, was strongly reduced by Kae. Histological studies demonstrated that Kae substantially inhibited LPS-induced alveolar wall thickness, alveolar hemorrhage and leukocytes infiltration in lung tissue with evidence of reduced myeloperoxidase (MPO) activity. Kae also efficiently increased superoxide dismutase (SOD) activity of lung sample when compared with LPS group, which was obviously reduced by LPS administration. In addition, Western blot analysis indicated that the activation of MAPKs and NF-κB signaling pathways stimulated by LPS was significantly blocked by Kae. Taken together, our results suggest that Kae exhibits a protective effect on LPS-induced ALI via suppression of MAPKs and NF-κB signaling pathways, which may involve the inhibition of tissue oxidative injury and pulmonary inflammatory process.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / chemically induced
  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / metabolism
  • Animals
  • Cell Movement / drug effects
  • Cytokines / metabolism
  • Inflammation Mediators / metabolism
  • Kaempferols / administration & dosage*
  • Lipopolysaccharides / immunology
  • MAP Kinase Signaling System / drug effects*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • NF-kappa B / metabolism*
  • Oxidative Stress / drug effects
  • Peroxidase / metabolism
  • Pulmonary Edema / chemically induced
  • Pulmonary Edema / drug therapy*
  • Pulmonary Edema / metabolism

Substances

  • Cytokines
  • Inflammation Mediators
  • Kaempferols
  • Lipopolysaccharides
  • NF-kappa B
  • kaempferol
  • Peroxidase